{"product_id":"global-companion-diagnostics-market-size-study-forecast-by-technology-immunohistochemistry-ihc-polymerase-chain-reaction-pcr-in-situ-hybridization-ish-real-time-pcr-rt-pcr-gene-sequencing-and-other-technologies-by-indication-lung-cancer","title":"Global Companion Diagnostics Market Size study \u0026 Forecast, by Technology (Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Real-time PCR (RT-PCR), Gene Sequencing and Other Technologies) by Indication (Lung Cancer,","description":"\u003cp\u003eGlobal Companion Diagnostics Market Size study \u0026amp; Forecast, by Technology (Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Real-time PCR (RT-PCR), Gene Sequencing and Other Technologies) by Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma and Other Indications), By End User (Pharmaceutical \u0026amp; Biopharmaceutical Companies, Reference Laboratories, CROs and Others)and Regional Analysis, 2022-2029\u003cbr\u003e\nGlobal Companion Diagnostics Market is valued at approximately USD 6.80 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 11.0% over the forecast period 2022-2029. A companion diagnostic is a test used to ensure the usage of a comparable biological product or medication is both safe and effective. These tests are typically used to diagnose cancer. In this, an appropriate medicine is recommended based on the identified biomarker. Based on a particular patient's response, these tests offer personalized treatment. The Companion Diagnostics market is expanding because of factors such as the increasing incidence of Cancer and rising Regulatory Approvals of New Tests for Different Indications.\u003c\/p\u003e\n\n\u003cp\u003eThe rising prevalence of cancer globally is fostering market growth, according to statistics published by the World Health Organization (WHO) in February 2022, approximately 400,000 children develop cancer worldwide every year. Also, according to the statistics published by the World Cancer Research Fund International, in 2020, there were 18,094,716 million cases of cancer diagnosed globally. The International Agency for Research on Cancer estimated increase in the worldwide burden of cancer is to 27.5 million new cases by 2040. The usage of these tests is increasing due to the increased incidence of cancer worldwide, which is boosting the market's expansion. Also, it is anticipated that regulatory approvals of these tests for various indications will expand the market. For instance, in August 2022, the U.S. FDA approved Thermo Fisher Scientific Inc.'s Oncomine Dx Target Test as a companion diagnostic (CDx). This test identifies non-small cell lung cancer tumours that exhibit HER2 (ERBB2) activating mutations (SNVs \u0026amp; Exon 20 Insertion). In addition, the co-development of drug and diagnostic technology and favorable government support is creating lucrative growth in the market. However, the high cost of drug development and associated clinical trials may halt market growth.\u003c\/p\u003e \n\n\u003cp\u003eThe key regions considered for the Global Companion Diagnostics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the rising drug discovery activities, rising prevalence of diseases and rising regulatory approvals in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising disease prevalence, an increase in the number of collaborations for drug development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.\u003c\/p\u003e\n\n\u003cp\u003eMajor market player included in this report are:\u003cbr\u003e\nAbbott Laboratories\u003cbr\u003e\nAgilent Technologies Inc.\u003cbr\u003e\nF.Hoffmann-La Roche Ltd\u003cbr\u003e\nBiomerieux SA\u003cbr\u003e\nQiagen NV\u003cbr\u003e\nSiemens Healthcare Gmbh\u003cbr\u003e\nThermo Fisher Scientific Inc.\u003cbr\u003e\nDanaher Corporation (Beckman Coulter Inc.)\u003cbr\u003e\nAlmac Group\u003cbr\u003e\nIllumina Inc.\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\n? In January 2022, Amoy Diagnostics Co. Ltd., and PREMIA Holdings (HK) Limited introduced the AmoyDx Pan Lung Cancer PCR Panel (the \"\"PLC Panel\"\") in Japan as a reimbursed companion diagnostic for various anti-cancer drugs.\u003cbr\u003e\n? In January 2021,In partnership with OmniSeq Corporation, Laboratory Corporation of America Holdings unveiled OmniSeq INSIGHTsm, a complete tissue-based test for genomic and immunological profiling that makes use of next-generation sequencing (NGS) technology. By advancing precision oncology, the test hopes to enhance patient outcomes..\u003c\/p\u003e\n\n\u003cp\u003eGlobal Companion Diagnostics Market Report Scope:\u003cbr\u003e\nHistorical Data 2019-2020-2021\u003cbr\u003e\nBase Year for Estimation 2021\u003cbr\u003e\nForecast period 2022-2029\u003cbr\u003e\nReport Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered Technology, Indication, End User Region\u003cbr\u003e\nRegional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Technology offerings of key players. The detailed segments and sub-segment of the market are explained below:\u003c\/p\u003e\n\n\u003cp\u003eBy Technology:\u003cbr\u003e\nImmunohistochemistry (IHC)\u003cbr\u003e\nPolymerase Chain Reaction (PCR)\u003cbr\u003e\nIn-situ Hybridization (ISH)\u003cbr\u003e\nReal-time PCR (RT-PCR)\u003cbr\u003e\nGene Sequencing\u003cbr\u003e\nOther Technologies\u003c\/p\u003e\n\n\u003cp\u003eBy Indication:\u003cbr\u003e\nLung Cancer\u003cbr\u003e\nBreast Cancer\u003cbr\u003e\nColorectal Cancer\u003cbr\u003e\nLeukemia\u003cbr\u003e\nMelanoma\u003cbr\u003e\nOther Indications\u003cbr\u003e\nBy End User:\u003cbr\u003e\nPharmaceutical \u0026amp; Biopharmaceutical Companies\u003cbr\u003e\nReference Laboratories\u003cbr\u003e\nCROs\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Region:\u003cbr\u003e\nNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nRoLA\u003cbr\u003e\nRest of the World\u003c\/p\u003e\n\n\u003cp\u003eCompanies Mentioned\u003cbr\u003e\nAbbott Laboratories\u003cbr\u003e\nAgilent Technologies Inc.\u003cbr\u003e\nF.Hoffmann-La Roche Ltd\u003cbr\u003e\nBiomerieux SA\u003cbr\u003e\nQiagen NV\u003cbr\u003e\nSiemens Healthcare Gmbh\u003cbr\u003e\nThermo Fisher Scientific Inc.\u003cbr\u003e\nDanaher Corporation (Beckman Coulter Inc.)\u003cbr\u003e\nAlmac Group\u003cbr\u003e\nIllumina Inc.\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ 200 Pages \/ MCW16229805","offer_id":47647003902258,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-companion-diagnostics-market-size-study-forecast-by-technology-immunohistochemistry-ihc-polymerase-chain-reaction-pcr-in-situ-hybridization-ish-real-time-pcr-rt-pcr-gene-sequencing-and-other-technologies-by-indication-lung-cancer","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}